CSM Technologies IPO is today.
9MFY26 PAT already beats FY25.
Yet receivable days are 129 and borrowings have surged.
Growth story or balance sheet risk?
https://t.co/WmOwgAWrqv
#IPO#StockMarket
Dhanwel Hybrid Seeds IPO opens today.
PAT surged 3.2x from ₹1.91 Cr to ₹6.12 Cr.
Revenue doubled, EBITDA jumped 3.3x, and the IPO is priced at just 10.35x P/E.
Undervalued growth story?
https://t.co/nS75LCtUPj
#IPO#DhanwelHybridSeeds
CSM Technologies IPO opens today.
PAT up, margins improving.
But debt jumped from ₹5.6 Cr to ₹74.5 Cr.
Priced at 30.37x P/E.
Can earnings growth justify the valuation?
https://t.co/WmOwgAWrqv
#IPO#CSMTechnologies
India's only cruise operator.
FY26 PAT: ₹5.21 Cr.
Debt: ₹101.9 Cr.
IPO P/E: 100.74x.
Investors are paying for future ships, not current profits.
Full Review
https://t.co/Cs9JDrIkjO
#IPO#CordeliaCruises
Revenue jumped 5.8x to ₹693 Cr. Debt: ₹0.
Yet Day 1 subscription is only 0.31x and GMP is just ₹2.
What is the market worried about?
Turtlemint Fintech IPO: growth, losses, valuation, risks & outlook decoded.
Full analysis👇
https://t.co/RDygTv8dmn #ipo
SME IPOs dramatically outperformed Mainboard IPOs on listing day in 2026.
Average Listing Gain:
• SME: 14.13%
• Mainboard: 1.85%
That's nearly 8x higher listing gains in the SME segment.
Full IPO GMP vs Listing Study:
https://t.co/yOifvfy8a8
#IPO#SMEIPO#StockMarket#Investing
PAT tripled.
P/E just 10.91x. GMP ₹70.
Yet this SME IPO is still under the radar.
Avience Biomedicals: revenue growth, margin expansion, RoNW 49.89%, risks & valuation decoded.
Detailed analysis by MrMoneyFrugal 👇
https://t.co/kxOHqY8zIc #ipo
How accurate is IPO GMP?
We analysed 82 IPOs listed in 2026.
Result:
• 50 IPOs had a GMP signal
• GMP got the listing direction right in 38 cases
• Directional accuracy: 76%
That's roughly 3 out of every 4 IPOs.
https://t.co/yOifvfy8a8
#IPO#GMP#StockMarket#mrmoneyfrugal
PAT jumped 8x in just 2 years.
Yet Anubhav Plast IPO is priced at a P/E of only 10.66x.
Revenue is growing, margins are expanding, but debt remains a key watchpoint.
Check full analysis at:
https://t.co/LReq6LUqCX
#IPO#AnubhavPlastIPO#SMEIPO#StockMarket
🔥 Listing Gain: 46.60%
With a GMP of ₹75 and a massive 282.87x subscription, investor demand was off the charts.
Did it meet your expectations?
Check full analysis at:
https://t.co/wrqyo0Iah7
#HorizonReclaimIPO#IPOListing#SMEIPO#StockMarket#Investing
Clay Craft IPO closed with a massive 95.35x subscription!
PAT has doubled, profitability improved, and the IPO is priced at a P/E of just 11.38x.
Will strong demand lead to a blockbuster listing?
Check full analysis at:
https://t.co/3Ofkj6aUIU
#ClayCraftIPO#IPO#SMEIPO
₹693 Cr revenue from ₹119 Cr in just one year. But there's a catch.
Turtlemint Fintech's revenue jumped 5.8x, yet FY25 loss stood at ₹194 Cr.
Zero debt, improving EBITDA, but profitability remains elusive.
Full Analysis by MrMoneyFrugal.
https://t.co/RDygTv8LbV
#ipo
PAT jumped 3.7x.
EBITDA surged 4.3x.
But debt exploded to ₹38.97 Cr.
Is Riyaasat Lifestyle a premium growth story or a leverage risk?
Full IPO analysis by MrMoneyFrugal.
https://t.co/CRsSfMRL2M
#IPO#StockMarket
PAT tripled. RoNW near 50%.
Yet Avience Biomedicals IPO is priced at just 10.91x FY25 earnings.
Cheap growth story or hidden risk?
Full IPO review.
https://t.co/kxOHqY8zIc
#IPO#StockMarket
PAT doubled.
EBITDA margin at 23.3%. P/E just 11.38x.
Is Clay Craft IPO being overlooked?
Check detailed analysis by MrMoneyFrugal:
https://t.co/3Ofkj6bsys
#ipo
Horizon Reclaim India IPO subscribed 7.65x on Day 1.
•Revenue: ₹20 Cr → ₹50 Cr
•PAT: ₹0.7 Cr → ₹10.5 Cr
•P/E: 13.97x
Borrowings rose to ₹35.8 Cr, but the IPO will partly repay debt.
With 2 days left, can demand accelerate further?
https://t.co/wrqyo0Iah7
#IPO#Investing